Table 2 Results of between-group meta-analyses based on type of vaccine and disease category
Sub-group | Comparison | No. studies | No. participants | No. events | Meta-analysis | Heterogeneity | |||
|---|---|---|---|---|---|---|---|---|---|
Effect size (%) | 95% Confidence interval (%) | p value | I2 (%) | p value | |||||
Type of vaccine pair-wised | mRNA vs. inactivated | 38 | 23,028 | 2409 | 6.58 | 4.57–8.89 | 0.0036 | 98.2 | 0 |
mRNA vs. vector | 33 | 21,124 | 2468 | 6.60 | 4.34–9.19 | 0.0788 | 97.9 | 0 | |
Vector vs. inactivated | 17 | 13,538 | 651 | 1.37 | 0.11–3.51 | 0.5969 | 95.8 |  < 0.0001 | |
Disease category | Rheumatologic and musculoskeletal | 34 | 43,894 | 3020 | 7.25 | 5.2–9.58 |  < 0.0001 | 96.1 | 0 |
Gastroenterological | 6 | 9832 | 1395 | 7.86 | 1.61–18.11 | 99.7 | |||
Dermatological | 6 | 2386 | 138 | 4.81 | 1.29–9.70 | 89.7 | |||
Neurological | 16 | 12,212 | 473 | 2.62 | 1.49–4.04 | 95.2 | |||
Nephrological | 2 | 93 | 27 | 26.66 | 8.16–50.59 | 82.1 | |||
Hematologic | 8 | 1186 | 150 | 14.12 | 3.77–28.39 | 95.0 | |||